Does Spironolactone Work for Hair Loss?
This is a research-based fact check, not medical advice. The findings summarized here come from peer-reviewed studies and are presented without added opinions. Consult a certified healthcare practitioner before making any treatment decision.
Verdict
Spironolactone is used off-label for female pattern hair loss and has growing evidence from observational studies and small RCTs showing benefit in women. It is not FDA-approved for hair loss. It works by blocking androgen receptors and reducing androgen production. It is not appropriate for men due to feminising side effects. Evidence quality is improving but remains below the standard of approved treatments.
Key takeaways
- Spironolactone is not FDA-approved for hair loss.
- Used off-label for female pattern hair loss based on its anti-androgen mechanism.
- Evidence from observational studies and small RCTs supports benefit in women.
- Not appropriate for men due to feminising side effects.
- Contraindicated in pregnancy due to potential fetal harm.
- Often combined with topical minoxidil in women who do not respond adequately to minoxidil alone.
What spironolactone is
Spironolactone is a potassium-sparing diuretic approved for heart failure, hypertension, and edema. Its anti-androgenic properties (blocking aldosterone receptors and androgen receptors, and reducing androgen production) have led to its off-label use for acne and female pattern hair loss (FPHL). It is the most commonly prescribed off-label anti-androgen for FPHL in the United States. Context on all evidence-based treatment options is in the hair restoration guide.
Clinical evidence in women
The Aleissa 2023 analysis of women with FPHL treated with spironolactone found significant improvement in hair density scores compared to baseline. The 2023 systematic reviews of oral spironolactone for FPHL found directionally positive results across multiple observational studies and small trials. The 2025 premenopausal RCT added controlled trial evidence showing spironolactone improved hair outcome measures vs comparator in premenopausal women.
The evidence base is improving in quality over time, moving from observational studies to controlled trials. However, no large, multicentre, placebo-controlled RCT comparable to the pivotal finasteride or minoxidil trials has been published. Most studies are small (fewer than 200 participants) and follow-up is typically under 12 months.
Why it is used in women specifically
Spironolactone's anti-androgenic mechanism makes it theoretically appropriate for androgen-driven hair loss. Female pattern hair loss often has an androgen component, and spironolactone may reduce the androgen signalling at the follicle that drives miniaturisation. It is not used in men because the same anti-androgenic mechanism causes feminising side effects (gynaecomastia, breast tenderness, sexual dysfunction) at the doses used for hair loss.
Dosing and monitoring
Common doses for hair loss range from 50-200mg daily. Spironolactone can cause electrolyte abnormalities (elevated potassium) and blood pressure changes, particularly at higher doses. Serum electrolytes and blood pressure are typically monitored when starting or adjusting the dose. As a prescription drug, its use for hair loss should be supervised by a doctor.
| Study | Patients | Key finding |
|---|---|---|
| Aleissa 2023: spironolactone for female hair loss | Observational | Significant improvement in hair density scores in women with FPHL on spironolactone. |
| 2023: oral spironolactone for female pattern hair loss | Systematic review | Directionally positive evidence in women. No large RCT comparable to approved treatments. |
| 2025: spironolactone premenopausal RCT | RCT | Controlled trial evidence showing improvement in hair outcomes in premenopausal women. |
What the research cannot tell you
- The optimal dose for hair loss in women, as large dose-response trials have not been conducted.
- Long-term (2-5 year) outcomes on continuous spironolactone for hair loss.
- How spironolactone compares directly to oral minoxidil in women with FPHL in a head-to-head RCT.
- Whether spironolactone is effective in women without elevated androgen levels.